ClinicalTrials.gg
RecruitingNCT05978362CAP-LATARJETUpdated May 13, 2026

Value of Capsular Repair for Latarjet

An interventional study of Latarjet technique in Shoulder Pain, sponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Shoulder Pain with a site in France — 3 open to participants now, 3 under way, none of them phase 3. Shoulder Pain · France.

Started
2023
with 1 other
No phase
9 of 10
3 open now
Registered
6th of 10
by date
Lead sponsor
2 of 10
GCS Ramsay Santé pour l'Enseignement et la Recherche

Among the 10 studies in Shoulder Pain with a site in France, this one is one of 2 that started in 2023, is one of 9 with no phase, and was the 6th registered.

Shoulder Pain

738 studies on the registry are indexed under Shoulder Pain; 168 are open to participants now.

Browse Shoulder Pain studies →

Open to participants now

3 of the 10 studies in Shoulder Pain with a site in France are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 90 Shoulder Pain studies recruiting now, 25 (28%) set no upper age limit and 55 (61%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Shoulder Pain with a site in France, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the occurrence of osteoarthritis (YES/NO) by radiography.

Read the detailed description

This is a prospective, comparative, longitudinal, randomized, single-blind, multicenter study.

This study will validate preliminary results on a technique associating capsular repair with abutment according to Latarjet in the treatment of shoulder instabilities. It may help reduce the risk of osteoarthritis and thus allow patients to maintain a healthy, stable and painless shoulder for longer.

03

Conditions studied

  • Shoulder Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient, male or female, over the age of 18
  • Patient with shoulder instability with risk factors for recurrence (ISIS score > 3), requiring surgical stabilization by abutment
  • Affiliated patient or beneficiary of a social security scheme
  • Patient having been informed and having given his free, informed and written consent.

Exclusion criteria

Exclusion Criteria:

  • Patient with history of surgery for instability of the same shoulder
  • Patient presenting to the realization of a postoperative scanner
  • Patient whose physical and/or psychological health is severely impaired, which according to the investigator may affect the compliance of the study participant
  • Patient participating in another clinical research or in a period of exclusion from another research still in progress at the time of inclusion
  • Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision
  • Pregnant, breastfeeding or parturient woman
  • Patient hospitalized without consent.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
86 participants (estimated)

Study arms

  • Experimental
    With capsular repair

    This technique consists of inserting the capsule during the operation according to Latarjet.

    Procedure: Latarjet technique

  • Active comparator
    Without capsular repair

    Latarjet technique without capsular repair

    Procedure: Latarjet technique

Interventions

  • ProcedureLatarjet technique

    Realization of a stop according to Latarjet

06

What researchers measure

Primary outcomes

  1. occurrence of osteoarthritis

    Change from occurrence of osteoarthritis (YES/NO) on X-ray at 5 and 10 years, compared to inclusion X-ray using the Samilson-Prieto classification.

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2037, 170 months after the start.

Of 351 non-industry interventional studies with no phase under Shoulder Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 170 months is above that.

Counting every sponsor, half of 356 studies reached it within 11 months; a quarter within 4 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2023
First posted
Aug 7, 2023
StartActual
Oct 11, 2023
Primary completionEst.
Dec 2037
CompletionEst.
Dec 2037
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05978362
Collaborators
Euraxi Pharma
Responsible party
Sponsor
First posted
Aug 7, 2023
Start date
Oct 11, 2023
Primary completion
Dec 2037 (estimated)
Completion
Dec 2037 (estimated)
Last update
May 13, 2026

Study contacts

Geoffroy NOURISSAT, MD
Contact
gnourissat@wanadoo.fr
768513650 ext. +33

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion